{"entity":{"id":"nct07312422","kind":"trial","name":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","aka":[],"tldr":"A phase 1/2 trial of pucotenlimab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by Zhejiang Provincial People's Hospital, now recruiting.","summary":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study is a phase 1/2, interventional study registered as NCT07312422 by Zhejiang Provincial People's Hospital, with a registry enrolment figure of 10 participants, started 2025-09-30 and due to reach its primary completion in 2026-04-30. Interventions recorded: Low-dose Radiotherapy; Pucotenlimab; AG regimen; FOLFIRINOX regimen. Conditions listed: Pancreatic Cancer; PD-L1; PD-1 Inhibitor; LDRT; Proterizumab. Primary outcome: ORR. Pancreatic eligibility wording from the registry: \"* Patients with histologically or cytologically confirmed pancreatic malignancy;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07312422","url":"https://clinicaltrials.gov/study/NCT07312422"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt"],"targets":[],"drugs":["pucotenlimab","gemcitabine-nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07312422","phase":"1/2","setting":"An Open-label, Single-center, Single-arm Study to Evaluate the Efficacy and Safety of Low-dose Radiation Therapy Combined With Pultelimab and Standard Treatment in Patients With Advanced Pancreatic Cancer","sponsor":"Zhejiang Provincial People's Hospital","enrolled":10,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07312422/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"},{"id":"pucotenlimab","kind":"drug","name":"Pucotenlimab","route":"/drugs/pucotenlimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}